Garakani, Amir

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 440

Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature: Toxic Effects of Nitrous Oxide Abuse

Garakani, A., Jaffe, R. J., Savla, D., Welch, A. K., Protin, C. A., Bryson, E. O., & McDowell, D. M. (2016) · The American Journal on Addictions

Forensic Toxicology and Drug AnalysisPoisoning and overdose treatments

Cited by 279

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 180

Comorbidity of irritable bowel syndrome in psychiatric patients: A review

Garakani, A., Win, T., Virk, S., Gupta, S., Kaplan, D., & Masand, P. S. (2003) · American Journal of Therapeutics

Gastrointestinal motility and disordersPsychosomatic Disorders and Their Treatments

Cited by 149

PROINFLAMMATORY AND “RESILIENCY” PROTEINS IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION: Cytokines, Resiliency Proteins and Major Depression

Martinez, J. M., Garakani, A., Yehuda, R., & Gorman, J. M. (2012) · Depression and Anxiety

Tryptophan and brain disordersTreatment of Major Depression

Cited by 131